Connect BiopharmaCNTB
Market Cap: $69.1M
About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Employees: 81
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 12 [Q1] → 12 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.77% less ownership
Funds ownership: 7.17% [Q1] → 5.4% (-1.77%) [Q2]
34% less capital invested
Capital invested by funds: $6.87M [Q1] → $4.52M (-$2.34M) [Q2]
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 30 / 108 met price target | 540%upside $8 | Buy Reiterated | 6 Sept 2024 |
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 30 / 108 met price target | 540%upside $8 | Buy Reiterated | 13 Jun 2024 |